CLICK HERE TO REGISTER!

Session 5: Targeting EGFR, T790M, ALK, and ROS1 in NSCLC

8:00am – 9:00am

Program Overview

Oncology treatment teams are tasked with navigating through a steady increase in the number and complexity of molecular biomarkers that guide treatment decisions. FDA-approved companion tests have expanded testing options and provide uniformity of reporting, yet challenges in the clinical setting and the potential to negatively impact patient outcomes persist. As part of the continuum of care in oncology, there is an increasing demand for genomic testing to guide the course of treatment.

Misinterpretation and over-interpretation of biomarker and genomic tests can be confusing. There is no shortage of targeted agents for the well-established molecular subtypes of non-small cell lung cancer (NSCLC); however, selecting the right agents for the right patients remains a challenge in the community setting.

Appropriate evidence-based and quality care will directly affect reimbursement and incentives within the new payment models.

Learning Objectives

  • Incorporate treatment pathways and quality measures to ensure patients receive guideline-consistent care
  • Evaluate the sequential and combination administration of targeted agents to optimize survival for patients with lung cancer
  • Discuss current recommendations for diagnostic testing for lung cancer to facilitate treatment selection
  • Assess the safety and efficacy of currently approved and emerging agents for primary and subsequent management of lung cancer with attention to cost/benefit and toxicity considerations
  • Evaluate communication strategies and resources to increase patient access and engagement

CME/CPE/CNE Information

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacists

Pharmacists – The Potomac Center for Medical Education is accredited by the Accreditation Council for Pharmacy education as a provider of continuing pharmacy education.

The Potomac Center for Medical Education designates this educational activity for a maximum of 1.0 hour (0.10 CEUs) of continuing education credit (UAN: 0418-9999-17-7211-L04-P).

This is an application-based activity.

Nurses

1.0 ANCC Contact hours provided by Postgraduate Institute for Medicine

Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This educational activity for 1.0 contact hours is provided by Postgraduate Institute for Medicine. Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

A statement of credit will be issued only upon receipt of a completed activity evaluation.

Disclosure Information

Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.

FDA Disclosure

The contents of some CME/CPE/CNE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

Method of Participation

To complete the activity and receive credit, the participant must attend the program and complete the evaluation form. A certificate will be provided after submission of a completed evaluation form.

There is no fee associated with this program.

Special Services

Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc).  Please contact MEDX Conference Planning prior to the live event at medx@mededexchange.com.

Jointly provided by The Potomac Center for Medical Education, Postgraduate Institute of Medicine, and Rockpointe Oncology

                  

This activity is supported by independent educational grants from AstraZeneca, Celgene Corporation, Lilly, Novartis Pharmaceutical Corporation and Sanofi Genzyme.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Faculty Information


Benjamin Levy, MD
Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Cancer Center,
Washington, DC